Chowdary, P. Et Al. 2020. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. HAEMOPHILIA , vol.26, no.4 .

Chowdary, P., Mullins, E. S., Konkle, B. A., McGuinn, C., Park, Y. S., Stasyshyn, O., ... Zulfikar, B.(2020). Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. HAEMOPHILIA , vol.26, no.4.

Chowdary, Pratima Et Al. "Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A," HAEMOPHILIA , vol.26, no.4, 2020

Chowdary, Pratima Et Al. "Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A." HAEMOPHILIA , vol.26, no.4, 2020

Chowdary, P. Et Al. (2020) . "Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A." HAEMOPHILIA , vol.26, no.4.

@article{article, author={Pratima Chowdary Et Al. }, title={Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A}, journal={HAEMOPHILIA}, year=2020}